PLoS One:HDAC6与抑郁症相关

2012-02-24 MedSci MedSci原创

近日,日本研究人员发现脑部神经细胞内含量很高的一种蛋白质与抑郁症有关。如果阻碍这种蛋白质发挥作用,能获得与使用抗抑郁药物相同的效果。相关报告已刊登在美国科学杂志《科学公共图书馆—综合》PLoS One的网络版上。日本爱知县身心障碍者精神发育障碍研究所与名古屋市立大学研究人员发现,在大脑发育时,一种名为HDAC6的蛋白质会增多。而在产生血清素的神经细胞中,也含有很多这种蛋白质。血清素对调节不安等情绪

近日,日本研究人员发现脑部神经细胞内含量很高的一种蛋白质与抑郁症有关。如果阻碍这种蛋白质发挥作用,能获得与使用抗抑郁药物相同的效果。相关报告已刊登在美国科学杂志《科学公共图书馆—综合》PLoS One的网络版上。

日本爱知县身心障碍者精神发育障碍研究所与名古屋市立大学研究人员发现,在大脑发育时,一种名为HDAC6的蛋白质会增多。而在产生血清素的神经细胞中,也含有很多这种蛋白质。血清素对调节不安等情绪发挥着重要作用。

研究人员让体内不含HDAC6蛋白质的小鼠与普通小鼠一起运动,结果发现,与普通小鼠相比,没有这种蛋白质的小鼠能多运动1分钟。懒于运动是抑郁症的症状之一。此外,没有这种蛋白质的小鼠在新环境中也显得更活跃,在很高的地点不会感到不安。

研究人员随后给一些普通小鼠服用了阻碍这种蛋白质发挥作用的药物。结果发现,小鼠在服用这种药物后,运动时间比正常情况下延长1分钟。这表明,如果阻碍这种蛋白质发挥作用,能获得与使用抗抑郁药物相同的效果。

研究人员川口祯晴指出,这一发现有望帮助弄清抑郁症的病理和开发出新的抗抑郁药物。

doi:10.1371/journal.pone.0030924
Loss of Deacetylation Activity of Hdac6 Affects Emotional Behavior in Mice

Masahide Fukada1, Atsuko Hanai1, Atsuo Nakayama1, Takayoshi Suzuki2, Naoki Miyata2, Ramona M. Rodriguiz3, William C. Wetsel3, Tso-Pang Yao4, Yoshiharu Kawaguchi1*

Acetylation of the ε-amino group of lysine is a reversible post-translational modification mediated by acetyltransferases and deacetylases. This type of acetylation is not restricted to histones but also occurs on diverse proteins and affects functions such as DNA binding, protein-protein interaction, enzymatic activity, and stability. Therefore, lysine acetylation emerges as an important post-translational modification that regulates a wide range of cellular processes (reviewed in [1]). Histone deacetylases (HDACs) are a family of enzymes with 18 isoforms in mammals, and are grouped into four classes by sequence homology [2]. HDAC6 belongs to class II, and has a unique structure with two catalytic domains and a C-terminal BUZ domain that binds ubiquitin. HDAC6 gene is located on X chromosome both in mice and human genome [3], [4]. In mice, Hdac6 protein is broadly expressed in multiple tissues, particularly abundant in the brain and testis (Fig. S1) [5]. HDAC6 is known to be a multi-functional cytoplasmic deacetylase that controls cell motility [6]–[9], endocytosis [10], vesicle transport [11], glucocorticoid receptor maturation [12], autophagic protein degradation [13]–[15], and aggresome formation [16] by deacetylating α-tubulin, cortactin, and Hsp90. These cellular events are closely related to the acquisition and maintenance of proper function in neurons. For example, at synapses, vesicle transport and endocytosis are underlying mechanisms for neurotransmitter release and recycling. Glucocorticoid receptor maturation is necessary for the negative feedback regulation of stress at the hippocampus [17]. Autophagic protein degradation and aggresome formation are a part of the quality control of proteins, and their disturbance leads to neurodegenerative disorders [18]. Despite the fact that Hdac6 protein is abundantly expressed in mice brain, the physiological implications of Hdac6 as well as non-histone acetylation in neural function are poorly understood. In this study, we found that Hdac6 is highly expressed in serotonergic neuron, and that loss of Hdac6 deacetylase activity leads to hyperactivity, less-anxiety and antidepressant-like behavior in mice. Our findings suggest that Hdac6-mediated non-histone deacetylation plays crucial roles in the expression of emotional behaviors.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003396, encodeId=c58b2003396d2, content=<a href='/topic/show?id=86d585931d' target=_blank style='color:#2F92EE;'>#HDAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8593, encryptionId=86d585931d, topicName=HDAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 01 04:58:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789381, encodeId=16421e8938123, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Dec 26 14:58:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042117, encodeId=c263204211e59, content=<a href='/topic/show?id=32bd859943' target=_blank style='color:#2F92EE;'>#HDAC6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8599, encryptionId=32bd859943, topicName=HDAC6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 27 06:58:00 CST 2013, time=2013-01-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003396, encodeId=c58b2003396d2, content=<a href='/topic/show?id=86d585931d' target=_blank style='color:#2F92EE;'>#HDAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8593, encryptionId=86d585931d, topicName=HDAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 01 04:58:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789381, encodeId=16421e8938123, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Dec 26 14:58:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042117, encodeId=c263204211e59, content=<a href='/topic/show?id=32bd859943' target=_blank style='color:#2F92EE;'>#HDAC6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8599, encryptionId=32bd859943, topicName=HDAC6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 27 06:58:00 CST 2013, time=2013-01-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003396, encodeId=c58b2003396d2, content=<a href='/topic/show?id=86d585931d' target=_blank style='color:#2F92EE;'>#HDAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8593, encryptionId=86d585931d, topicName=HDAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 01 04:58:00 CST 2012, time=2012-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789381, encodeId=16421e8938123, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Dec 26 14:58:00 CST 2012, time=2012-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042117, encodeId=c263204211e59, content=<a href='/topic/show?id=32bd859943' target=_blank style='color:#2F92EE;'>#HDAC6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8599, encryptionId=32bd859943, topicName=HDAC6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Jan 27 06:58:00 CST 2013, time=2013-01-27, status=1, ipAttribution=)]
    2013-01-27 xzw113

相关资讯

EPCRC发布首部癌症姑息治疗抑郁症管理指南

  癌症患者在姑息治疗中发生抑郁很常见,为使临床医师有“据”可依地进行处理,欧洲姑息治疗研究协作组(EPCRC)在系统性回顾了现有循证医学证据并进行了德尔斐(Delphi)研究后,制定出欧洲第一部癌症姑息治疗抑郁症管理指南。相关内容参见《欧洲癌症杂志》 [Eur J Cancer 2011, 47(5): 702]。   姑息治疗中抑郁症的预

双语医学阅读:抑郁症疗法或改变

  New Depression Findings Could Alter Treatments   新的研究结果可能改变抑郁症的治疗方法   The results of two new studies may signal a substantial shift in the way psychiatrists and researchers think about treatment f

甲状旁腺切除术可改善抑郁症及心血管异常

原发性甲状旁腺机能亢进(PHP)患者伴有抑郁症或亚临床心血管异常正在成为新的甲状旁腺切除术适应证。PHP已不再局限于一种具有代谢性骨病、胃肠道功能紊乱和肾结石等典型临床表现的疾病,在常规进行血清钙测定的时代,多数患者并无症状,或报告情绪、认知和神经肌肉功能异常等非特异性症状。美国骨与矿物质研究协会年会上报告的研究提示,在PHP患者中,有临床意义的抑郁症患病率更高且更严重,并且亚临床心血管异常也更为

AFM:有伴随疾病的抑郁症患者亦可接受抗抑郁症治疗

德州大学西南医学中心的David W. Morris 博士等近日在《家庭医学年报》(Annals of Family Medicine)发表论文称,对有其他伴随疾病的重度抑郁症患者使用抗抑郁症治疗也是安全且有效的。作者通过二次分析发现,与没有伴随疾病的抑郁症患者相比,患有高血压、糖尿病、关节炎等3至4种伴随疾病的抑郁症患者的28周缓解率没有明显差别。 之前有研究称,伴随疾病会干扰抑郁症的治疗,患